Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review

J Am Coll Cardiol. 2020 Feb 4;75(4):435-447. doi: 10.1016/j.jacc.2019.11.036.

Abstract

Changes in the regulatory guidelines by the U.S. Food and Drug Administration and the European Medical Agency requiring large-scale trials that study the cardiovascular safety of new glucose-lowering drugs have improved our understanding of type 2 diabetes mellitus. Unexpectedly, these trials demonstrated that sodium-glucose cotransporter 2 inhibitors reduce adverse cardiovascular outcomes. This second part of this 2-part review summarizes the findings of recent clinical trials and their clinical implications and describes ongoing trials and future areas of research.

Keywords: cardiorenal interaction; diabetes; heart failure; renal function; sodium-glucose cotransporter 2 inhibitor.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / complications
  • Atherosclerosis / drug therapy
  • Blood Glucose / drug effects
  • Cardiovascular Diseases / drug therapy
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Disease Progression
  • Heart / drug effects*
  • Humans
  • Hypoglycemic Agents / pharmacology*
  • Kidney / drug effects*
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / drug therapy
  • Risk
  • Sodium-Glucose Transporter 2 Inhibitors / pharmacology*

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors